Clinical Trials Browser

Phase 1/2 × Neoplasms × Rifaximin × Clear all

NCT06783153 2025-01-20

Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients

Phase 1/2 Not yet recruiting

GastrointestinalGenitourinary

Neoplasms, Prostatic Neoplasms, Rectal Neoplasms